We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novo Nordisk has announced that effective Jan. 1, it will stop distributing discounted medications to community-based pharmacies of covered entity hospitals under the 340B Drug Pricing Program, joining other drugmakers who have taken similar steps to combat what they claim are duplicate discounts created under the program’s expansion to include contract pharmacies. Read More
A group of pharma industry investors is pressing several leading drugmakers to make their COVID-19 treatments and vaccines both affordable and accessible. Read More
Dolutegravir belongs to a class of drugs called HIV-integrase inhibitors that reduce the amount of HIV in the blood while boosting immune-cell production. Read More
The advantage of using AAV as a vector is that “it can achieve sustained expression of the antibodies in the nasal mucosa, which is the site of infection, following a single administration,” said UPenn’s lead researcher James Wilson. Read More
Regeneron has partnered with the University of Pennsylvania (UPenn) to develop a gene therapy nasal delivery system for its COVID-19 antibody cocktail, casirivimab and imdevimab, which received an Emergency Use Authorization from the FDA last month for mild-to-moderately ill coronavirus patients at high risk. Read More
The global police organization Interpol issued a warning yesterday to countries to prepare for a new wave of organized criminal activity, including cyber hacking of drugmakers as governments prepare to ship their vaccines. Read More
Wren has pioneered a new approach to protein misfolding diseases that uses a predictive method in place of the traditional drug discovery and biological approaches. Read More
AstraZeneca is selling off limited rights to its former blockbuster statin drug Crestor to Grünenthal for $320 million upfront and possible future milestone payments of up to $30 million. Read More
Novavax said it will begin a delayed phase 3 trial in the U.S. and Mexico to evaluate its COVID-19 vaccine candidate, NVX-CoV2373, “in the coming weeks” and that its 15,000-person late-stage trial in the UK is now fully enrolled. Read More